Compare Ascendis Pharma A/S (ASND) vs Vanguard Total International Bond Index Fund ETF (BNDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Total International Bond Index Fund ETF — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Vanguard Total International Bond Index Fund ETF trades at $48.03. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ASND | BNDX | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $49.91 |
52-Week Low | $163.32 | $47.57 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BNDX trades at $48.08 with minimal daily movement (+0.12%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators remain neutral. The ETF maintains consistent dividend distributions of $0.11 per share. Market sentiment reflects uncertainty around Federal Reserve policy direction and inflation concerns, with bond ETF flows showing increased investor interest in fixed income alternatives.
The outlook remains cautious amid Federal Reserve policy uncertainty and inflation pressures. While bond ETFs offer income stability, rising rate expectations pose headwinds for traditional bond funds. Investors should monitor Fed communications and inflation data for directional cues, with international bond exposure providing diversification benefits but facing currency and interest rate differential risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →
